Alloy Therapeutics Launches Proprietary AntiClastic™ Antisense Oligonucleotide Platform to Make Potent Genetic Medicine
AntiClastic™ Antisense Oligonucleotide (AntiClastic ASO) is a proprietary platform available exclusively through partnerships with Alloy. Sudhir Agrawal, D.Phil, inventor of the underlying IP for the AntiClastic ASO platform, to chair Alloy’s genetic medicines scientific advisory board (SAB). BOSTON, Mass. – June 28, 2023 — Alloy Therapeutics, a biotechnology ecosystem company, announced the launch of its […]
Alloy Therapeutics to Empower Drug Discovery of Lundbeck’s Biologics for Brain Health
BOSTON, Mass. – May 2, 2023 — Alloy Therapeutics, a biotechnology ecosystem company, announced it is collaborating with Lundbeck, a global pharmaceutical company specializing in brain diseases, in the discovery of novel biologics therapies. Through this agreement, Lundbeck will gain access to Alloy’s Antibody Discovery Services and its SeqImmune™ discovery module, which is a sequence-first workflow […]
Alloy Therapeutics Announces an Expansion of its Antibody Discovery Services in Conjunction with Two New Senior Vice Presidents
Alloy Antibody Discovery Services offers partners a modular campaign design that can meet their goals and budgets as they collaborate to discover the best antibodies with therapeutic potential. BOSTON, Mass. – April 26, 2023 — Alloy Therapeutics, a biotechnology ecosystem company, announced the appointment of Kent Bondensgaard and John “Lippy” Lippincott as the latest members […]
Alloy Therapeutics Unveils 2023 Innovation Roadmap Across Antibodies, TCRs, Bispecifics, and Genetic Medicines
— Alloy’s growing services portfolio reflects its commitment to empowering global scientific community with access to broad, foundational biologics discovery capabilities — BOSTON, MA; January 9, 2023—Alloy Therapeutics, a biotechnology ecosystem company, announced its 2023 roadmap of new discovery technologies and services across a range of biologic modalities. Alloy will support its community of 140+ partners […]
Alloy Therapeutics and Normunity Sign Multi-Program Antibody Discovery Collaboration in Immuno-Oncology
— Partnership leverages Alloy’s high velocity antibody discovery offering to accelerate Normunity’s novel precision immuno-oncology pipeline — BOSTON, MA; November 17, 2022—Alloy Therapeutics, a biotechnology ecosystem company, announced an antibody discovery collaboration spanning multiple precision immuno-oncology programs for Normunity, a biotech company that recently announced its $65 million Series A financing. The collaboration will support the […]
Alloy Therapeutics Raises $42 Million Series D Financing to Accelerate Discovery Technology Development Across Biologic Modalities
— Following a successful expansion from antibodies into T-cell receptors and genetic medicines, Alloy will broaden its pre-competitive discovery technology and discovery services to enable innovative new therapeutic formats — BOSTON, MA; October 03, 2022—Alloy Therapeutics, a biotechnology ecosystem company, has closed $42 million in Series D financing led by its existing investors 8VC and Mubadala […]
Alloy Therapeutics Hires People Executive Trier Bryant as President of Venture Studio, 82VS
—Trier will lead operations and strategy of people-focused venture studio, supporting ecosystem of scientific entrepreneurs— BOSTON, MA; September 07, 2022–Alloy Therapeutics, a biotechnology ecosystem company, welcomes Trier Bryant as President of 82VS, Alloy’s affiliated venture studio. Trier is a strategic executive leader with distinctive tech, Wall Street, and military experience spanning 15 years, and brings a […]
Alloy Therapeutics Ecosystem Offerings Go Intracellular Through Collaboration with Sudhir Agrawal in Genetic Medicines
–Through a partnership with antisense pioneer Agrawal’s Arnay Sciences, Alloy strengthens its mission to democratize enabling drug discovery technology for the global scientific community– BOSTON, MA; June 09, 2022–Alloy Therapeutics, a biotechnology ecosystem company, announced a collaboration and licensing agreement with Sudhir Agrawal’s Arnay Sciences to advance new RNA-based drug discovery platforms and novel chemistries spanning […]
ATX-Gx™ Biotech Licensee Discovering Novel Therapeutics
Alloy has more than 130 partners in the drug discovery ecosystem across academic, biotech, and large biopharma teams. Early in our history, we connected with Dren Bio, Inc., an emerging biopharmaceutical company headquartered in Northern California that specializes in the discovery of therapeutic antibodies engineered to selectively deplete pathologic cells and other disease-causing agents. Dren […]
How Alloy is Enabling the Discovery and Engineering of Chimeric Antigen Receptors for Cell Therapies
Cell therapy utilizing chimeric antigen receptors (CARs) for immunotherapy of cancer show great promise as treatments of blood cancers. CARs are composed of an antigen binding domain linked to a signaling domain, which collectively enables recognition of the cancer antigen and activation of the CAR-T cells. Therapeutically active CARs require high levels of antigen binding […]
